Archive July 20, 2020 China NMPA Accepts NDA Submission of Ripretinib for Advanced Gastrointestinal Stromal Tumor
Archive July 14, 2020 Deciphera Announces Australian Therapeutic Goods Administration’s Approval of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Archive July 2, 2020 Deciphera Announces Presentation of Analysis of Crossover Population from the INVICTUS Phase 3 Study of QINLOCK™ (ripretinib) in Patients with Fourth-Line Advanced GIST
Archive June 22, 2020 Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Archive June 11, 2020 Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Forum
Archive June 8, 2020 Deciphera Announces Publication of the INVICTUS Pivotal Phase 3 Study of QINLOCK™ (ripretinib) in The Lancet Oncology
Archive May 29, 2020 Deciphera Pharmaceuticals Presents Preliminary Data from Phase 1b/2 Study of Rebastinib in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer at the ASCO 2020 Virtual Scientific Program
Archive May 29, 2020 Deciphera Pharmaceuticals Announces Presentations of Positive Patient Reported Outcomes Results from INVICTUS Phase 3 Study of QINLOCK™ (ripretinib) in Patients with Fourth-Line Advanced GIST at the ASCO 2020 Virtual Scientific Program
Archive May 27, 2020 Deciphera Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference
Archive May 15, 2020 FDA Grants Full Approval of Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
